Trial Profile
A study of Eflapegrastim in the Management of Chemotherapy-Induced Neutropenia in Breast Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Nov 2016
Price :
$35
*
At a glance
- Drugs Eflapegrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- 17 Nov 2016 New trial record